市場調查報告書

口服抗糖尿病藥物的全球市場 - 磺醯尿素類、Meglitinides、雙胍類(Biguanides ) 、α-Glucosidase抑制劑

Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

出版商 Zion Market Research 商品編碼 522830
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
Back to Top
口服抗糖尿病藥物的全球市場 - 磺醯尿素類、Meglitinides、雙胍類(Biguanides ) 、α-Glucosidase抑制劑 Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022
出版日期: 2017年01月06日內容資訊: 英文 110 Pages
簡介

本報告提供全球糖尿病口服藥的市場未來展望相關分析,全球整體的市場趨勢預測 (總計7年份) ,及各類藥物、各地區的詳細趨勢,市場基本結構及主要推動及市場的阻礙要素,市場競爭環境 (市場佔有率結構,主要的資本交易趨勢等),主要企業的概要、業績、戰略構想等調查。

第1章 簡介

第2章 摘要整理

  • 全球口服抗糖尿病藥物市場:趨勢預測 (以金額為準,總計7年份)
  • 全球口服抗糖尿病藥物市場:概況

第3章 口服抗糖尿病藥物市場動態

  • 簡介
  • 價值鏈分析
  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 波特的五力分析
  • 市場向心力分析

第4章 全球口服抗糖尿病藥物市場:競爭環境

  • 市場佔有率分析 (最新值)
  • 策略發展情形
    • 企業合併、收購 (M&A)
    • 新產品的上市
    • 協定,產業聯盟,產業合作,合資企業
    • 研究開發 (R&D),其他地區進出
  • 產品系列

第5章 全球口服抗糖尿病藥物市場:各類藥物分析

  • 市場概要:各類藥物
    • 市場收益額佔有率:各類藥物 (最新值、預測值)
  • 磺醯尿素類
    • 全球磺醯尿素類市場:最新值、預測值 (以金額為準)
    • Glimepiride
    • Gliclazide
    • Glyburide
    • 其他
  • Meglitinides
    • 全球Meglitinides市場:最新值、預測值 (以金額為準)
    • Repaglinide
    • Nateglinide
  • 雙胍類(Biguanides )
    • 全球雙胍類(Biguanides ) 市場:最新值、預測值 (以金額為準)
    • Metformin
    • 其他
  • α-Glucosidase抑制劑
    • 全球α-Glucosidase抑制劑市場:最新值、預測值 (以金額為準)
    • Acarbose
    • boguribosu
    • 其他

第7章 全球口服抗糖尿病藥物市場:各地區的分析

  • 市場概要:各地區
  • 北美市場 (美國,加拿大)
  • 歐洲市場 (德國,法國,英國)
  • 亞太地區市場 (中國,日本,印度)
  • 南美市場 (巴西)
  • 中東、非洲市場

第7章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The report covers forecast and analysis for the oral antidiabetic drugs market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD billion). The study includes drivers and restraints of the oral antidiabetic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral antidiabetic drugs market on a global level.

In order to give the users a comprehensive view of the Oral antidiabetic drugs market, we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter's five forces model for the oral antidiabetic drugs market has also been included. The study encompasses a market attractiveness analysis, wherein the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the oral antidiabetic drugs market by segmenting the market based on drugs class and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. The drugs class segmentation includes sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. The meglitinides class is further segmented into repaglinide and nateglinide. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into U.S., Canada, China, Japan, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global oral antidiabetic drugs market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

This report segments the global oral antidiabetic drugs Market as follows:

Global Oral Antidiabetic Drugs Market: Drugs Class Analysis

  • Sulfonylureas
    • Glimepiride
    • Gliclazide
    • Glyburide
    • Others
  • Meglitinides
    • Repaglinide
    • Nateglinide
  • Biguanides
    • Metformin
    • Others
  • Alpha-glucosidase inhibitors
    • Acarbose
    • Voglibose
    • Others
  • Others

Global Oral Antidiabetic Drugs Market: Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
  • Middle East and Africa

Table of Contents

Chapter 1. Introduction

  • 1.1. Report Description And Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

Chapter 2. Executive Summary

  • 2.1. Global Oral Anti-Diabetic Market, 2016 - 2022 (USD Billion)
  • 2.2. Global Oral Anti-Diabetic Market: Snapshot

Chapter 3. Oral Anti-Diabetic - Market Dynamics

  • 3.1. Introduction
  • 3.2. Value Chain Analysis
  • 3.3. Market Drivers
    • 3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
    • 3.3.2. Rising Prevalence Of Diabetes Mellitus
    • 3.3.3. Increase In Obesity
  • 3.4. Market Restraints
    • 3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
    • 3.4.2. High Cost of Drugs
  • 3.5. Opportunities
    • 3.5.1. Market Strength
  • 3.6. Porter's Five Forces Analysis
    • 3.6.1. Bargaining Power Of Suppliers
    • 3.6.2. Bargaining Power Of Buyers
    • 3.6.3. Threat From New Entrants
    • 3.6.4. Threat From New Substitutes
    • 3.6.5. Degree Of Competition
  • 3.7. Market Attractiveness Analysis
    • 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
    • 3.7.2. Market Attractiveness Analysis, By Regional Segment

Chapter 4. Global Oral Anti-Diabetic Market - Competitive Landscape

  • 4.1. Company Market Share, 2016 (Subject To Data Availability)
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Type Launch
    • 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
    • 4.2.4. Research And Development, Regional Expansion
  • 4.3. Type Portfolio

Chapter 5. Global Oral Anti-Diabetic Market - Drug Class Analysis

  • 5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
    • 5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
  • 5.2. Sulfonylureas
    • 5.2.1. Global Sulfonylureas Market, 2016 - 2022 (USD Billion)
    • 5.2.2. Glimepiride
      • 5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.3. Gliclazide
      • 5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.4. Glyburide
      • 5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.5. Others
      • 5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.3. Meglitinides
    • 5.3.1. Global Meglitinides Market, 2016 - 2022 (USD Billion)
    • 5.3.2. Repaglinide
      • 5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.3.3. Nateglinide
      • 5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.4. Biguanides
    • 5.4.1. Global Biguanides Market, 2016 - 2022 (USD Billion)
    • 5.4.2. Metformin
      • 5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.4.3. Others
      • 5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.5. Alpha-glucosidase inhibitors
    • 5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 - 2022 (USD Billion)
    • 5.5.2. Acarbose
      • 5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.5.3. Voglibose
      • 5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.5.4. Others
      • 5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)

Chapter 6. Global Oral Anti-Diabetic Market - Regional Segment Analysis

  • 6.1. Global Oral Anti-Diabetic Market: Regional Overview
    • 6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
  • 6.2. North America
    • 6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.3.3. France
      • 6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.3.4. U.K.
      • 6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.2. China
      • 6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.4. India
      • 6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.6. Middle East And Africa
    • 6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)

Chapter 7. Company Profile

  • 7.1. Abbott Laboratories
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Biocon, Ltd
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Eli Lilly and Company
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Sun Pharma Industries, Ltd.
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. Novo Nordisk A/S
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Developments
  • 7.6. Pfizer
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Developments
  • 7.7. Sanofi
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Developments
  • 7.8. Novartis
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Developments
  • 7.9. Merck Group
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development

List of Figures

  • 1. Market Research Process
  • 2. Market Research Methodology
  • 3. Global Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 4. Porter's Five Forces Analysis
  • 5. Oral Anti-Diabetic: Market Attractiveness Analysis, By Drug Class Segment
  • 6. Oral Anti-Diabetic: Market Attractiveness Analysis, By Regional Segment
  • 7. Company Market Share Analysis, 2016 And 2022
  • 8. Global Oral Anti-Diabetic Market Revenue Share By Drug Class, 2016 And 2022
  • 9. Sulfonylureas Market, 2016 - 2022, (USD Billion)
  • 10. Glimepiride Market, 2016 - 2022, (USD Billion)
  • 11. Gliclazide Market, 2016 - 2022, (USD Billion)
  • 12. Glyburide Market, 2016 - 2022, (USD Billion)
  • 13. Others sulphonylureas Market, 2016 - 2022, (USD Billion)
  • 14. Meglitinides Market, 2016 - 2022, (USD Billion)
  • 15. Repaglinide Market, 2016 - 2022, (USD Billion)
  • 16. Nateglinide Market, 2016 - 2022, (USD Billion)
  • 17. Biguanides Market, 2016 - 2022, (USD Billion)
  • 18. Metformin Market, 2016 - 2022, (USD Billion)
  • 19. Others Market, 2016 - 2022, (USD Billion)
  • 20. Alpha-glucosidase inhibitors Market, 2016 - 2022, (USD Billion)
  • 21. Acarbose Market, 2016 - 2022, (USD Billion)
  • 22. Voglibose Market, 2016 - 2022, (USD Billion)
  • 23. Others Market, 2016 - 2022, (USD Billion)
  • 24. Global Oral Anti-Diabetic Market Share, By Region, 2016 - 2022
  • 25. North America Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 26. U.S. Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 27. Canada Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 28. Europe Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 29. Asia-Pacific Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 30. China Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 31. Japan Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 32. India Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 33. Latin America Oral Anti-Diabetic Market, 2016-2022, (USD Billion)
  • 34. Brazil Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 35. Middle East & Africa Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)

List of Tables

  • 1. Oral Anti-Diabetic Market: Market Snapshot
  • 2. Drivers Of Global Oral Anti-Diabetic Market: Impact Analysis
  • 3. Restraints Of Global Oral Anti-Diabetic Market: Impact Analysis
  • 4. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 5. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 6. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 7. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 8. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 9. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 10. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 11. Asia-Pacific Oral Anti-Diabetic Market Revenue, By Drug Class 2016 - 2022(USD Billion)
  • 12. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)
  • 13. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)
  • 14. The Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)
Back to Top